查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929649

口服胜肽类药物市场按剂型、分子类型、通路、应用和最终用户划分，全球预测（2026-2032年）

Oral Peptide Drugs Market by Form, Molecule Type, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，口服胜肽类药物市值将达到 48.4 亿美元，到 2026 年将成长至 52 亿美元，到 2032 年将达到 76.9 亿美元，复合年增长率为 6.82%。

关键市场统计数据
基准年 2025 48.4亿美元
预计年份：2026年 52亿美元
预测年份 2032 76.9亿美元
复合年增长率 (%) 6.82%

对科学突破、临床需求和医疗服务挑战的全面审视正在重塑口服胜肽疗法和相关人员的优先事项。

口服胜肽类药物代表生物活性分子递送方式的革命性转变，传统上此类药物只能透过肠外途径给药。近年来，製剂科学、渗透增强技术和递送平台的进步，已将胜肽类药物的潜力转化为可行的临床治疗选择，从而提高了患者的依从性，并开闢了新的治疗模式。本文概述了目前口服胜肽类药物的技术、商业性和监管格局，并指出了创新者必须克服的关键挑战，才能将分子层面的疗效转化为实际临床应用。

口服给药技术的进步、以患者为中心的护理模式以及不断变化的监管要求，如何加速肽类药物领域的策略调整

口服胜肽类药物的研发格局正经历一系列变革性转变，这些转变正在改变打入市场策略和投资重点。其中最主要的变化是口服给药技术的成熟，这些技术能够减少酵素降解并提高黏膜渗透性，从而拓展胜肽类药物的治疗潜力，使其不再局限于特定适应症。这一发展趋势促使製药公司重新评估其资产组合，并将重点放在那些口服製剂能够带来显着临床差异化的分子上。

评估截至2025年的关税调整如何改变了口服胜肽价值链的筹资策略、製造地选择和商业协议。

到2025年，一系列关税调整的累积影响正在显着改变企业采购关键原材料、建立製造地以及谈判商业条款的方式。某些化学前驱物、添加剂和设备的进口关税提高，凸显了供应链韧性和成本透明度的重要性。因此，企业在选择供应商时越来越重视关税风险，透过谈判签订长期合约来稳定到岸成本，并优先考虑拥有多元化物流路线和近岸生产能力的供应商。

基于深度细分的洞察，可优化针对不同治疗标靶、製剂形式、通路、临床环境和分子类别的开发和商业化方案。

细分市场分析揭示了不同治疗标靶、剂型、通路、终端用户环境和分子类别所带来的独特机会和技术要求。依照治疗应用进行考量，可以发现显着差异：针对心血管疾病的项目需要能够整合到慢性病治疗路径中的製剂和给药方案；糖尿病的研发涵盖DPP-4抑製剂、GLP-1类似物和胰岛素肽，每种药物都面临着独特的吸收和给药挑战；胃肠道疾病的研发优先考虑肠道稳定性和耐受性；而肿瘤药物，例如激酶和肿瘤药物，例如激酶和疫苗安全性的证据优先性证据。这些治疗领域的细微差别直接影响製剂的选择和临床开发计划。

区域监管环境、生产优势和疾病负担如何影响美洲、欧洲、中东和非洲以及亚太地区口服胜肽的商业化策略

区域趋势持续影响口服胜肽类药物的推广应用，在美洲、欧洲、中东和非洲以及亚太市场，各市场面临不同的机会和挑战。在美洲，创新中心和集中式支付系统促进了口服生物利用度高的胜肽类药物的早期应用，这些药物在提高患者依从性和治疗效果方面展现出显着优势；同时，完善的监管路径和商业基础设施也支持临床差异化候选药物的快速规模化生产。在欧洲、中东和非洲，由于法规环境的多样性和报销方式的波动，需要製定个人化的市场进入策略，以反映各国的卫生技术评估（HTA）流程和价格敏感度。

在不断发展的口服胜肽领域，绘製出策略联盟、生产规模化投资和授权授权集中形成竞争优势的领域图谱。

主要企业的活动特征是策略联盟、平台授权和对专业生产和製剂技术的定向投资。领先的製药和生物技术公司正大力投资适用于多种胜肽类药物的口服给药平台，而专业技术公司则专注于赋形剂、渗透促进剂和包封方法，以实现全身暴露。合约开发和生产组织 (CDMO) 正在扩大无菌和非无菌生产能力，以满足胜肽类原料药和最终製剂的生产需求，而服务供应商透过降低规模化生产风险的整合开发路径来实现差异化竞争优势。

为帮助经营团队透过平台投资、供应链韧性和基于证据的准入策略获得竞争优势，提供切实可行的策略建议。

产业领导者应采取整合、多维度的策略，将科学进步转化为永续的市场地位。优先投资于可广泛适用于各类胜肽的口服给药平台，同时推进分子特异性製剂的研发，以临床实验。加强与供应商的关係并实现采购地点的多元化，有助于降低关税和物流风险；而对区域生产和加工能力的定向投资，则可带来成本和前置作业时间的优势。

我们采用严谨的多方法研究途径，结合专家访谈、文献综合、监管文件审查和情境检验，来支持我们的策略结论。

支持这些发现的研究整合了来自多个资讯来源的定性和定量方法，以验证结果并最大限度地减少偏差。主要资料来源包括对研发主管、监管专家、生产主管、支付方和临床研究人员的结构化访谈，并辅以对同行评审文献、监管指导文件和公司资讯披露的综合分析。跨治疗领域和分子类型的比较分析采用了一致的框架来评估技术风险、临床开发复杂性和商业性考虑。

结论概述了一个切实可行的蓝图，该路线图结合了製剂创新、监管参与和商业性执行，以实现口服胜肽类药物的潜力。

总之，在递送科学的快速发展、策略伙伴关係以及以商业性为中心的医疗治疗方法理念的推动下，口服胜肽类药物正从概念性潜力走向切实可行的临床和商业现实。该领域的成功取决于一种整合策略，即根据不同治疗领域和区域市场的独特需求，将分子选择、製剂创新、监管策略和供应链设计相结合。积极应对技术风险、及早与支付方和监管机构沟通并建立灵活的生产体系的相关人员，将更有利于把科学进步转化为持续的市场进入和患者获益。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 口服胜肽类药物市场（依剂型划分）

  • 胶囊
  • 口服液
  • 口服悬浮液
  • 药片

9. 依分子类型分類的口服胜肽类药物市场

  • 修饰胜肽
  • 天然胜肽
  • 胜肽类似物

第十章 口服胜肽类药物市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 依应用分類的口服胜肽药物市场

  • 心血管疾病
  • 糖尿病
    • DPP-4抑制剂
    • GLP-1类似物
    • 胰岛素胜肽
  • 消化系统疾病
  • 肿瘤学
    • 激酶抑制剂
    • 胜肽疫苗

第十二章 依最终用户分類的口服胜肽类药物市场

  • 诊所
  • 居家医疗环境
  • 医院
  • 专业医疗中心

第十三章 各地区口服胜肽类药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 口服胜肽类药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国口服胜肽类药物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国口服胜肽类药物市场

第十七章：中国口服胜肽类药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biocon
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • i2o Therapeutics
  • Intract Pharma
  • Ipsen SA
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Protagonist Therapeutics, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-0A380695186C

The Oral Peptide Drugs Market was valued at USD 4.84 billion in 2025 and is projected to grow to USD 5.20 billion in 2026, with a CAGR of 6.82%, reaching USD 7.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.84 billion
Estimated Year [2026] USD 5.20 billion
Forecast Year [2032] USD 7.69 billion
CAGR (%) 6.82%

A comprehensive orientation to the scientific breakthroughs, clinical imperatives, and healthcare delivery challenges reshaping oral peptide therapeutics and stakeholder priorities

Oral peptide therapeutics represent a pivotal shift in the delivery of biologically active molecules historically constrained to parenteral administration. Recent advances in formulation science, permeation enhancement, and delivery platforms have transformed the promise of peptides into practical clinical options, enabling sustained patient adherence and new therapeutic paradigms. This introduction frames the technical, commercial, and regulatory contours that define the current landscape and identifies the primary challenges that innovators must overcome to translate molecular efficacy into real-world outcomes.

Clinicians and development teams now confront a distinct set of priorities: preserving molecular integrity through the gastrointestinal tract, achieving clinically meaningful systemic exposure without invasive devices, and ensuring consistent patient-centric dosing regimens. Concurrently, payers and healthcare systems are recalibrating evaluation frameworks to balance acquisition cost with downstream adherence and outcomes. By articulating the interplay between scientific innovation and healthcare delivery, this section sets the stage for the deeper analysis that follows, highlighting why oral peptide programs require integrated strategies across formulation development, clinical evidence generation, manufacturing scalability, and market access planning.

How advances in oral delivery technologies, patient-centric care models, and evolving regulatory expectations are accelerating strategic realignment across the peptide therapeutics sector

The landscape of oral peptide drug development is being reshaped by a series of transformative shifts that are altering go-to-market strategies and investment priorities. Chief among these shifts is the maturation of oral delivery technologies that mitigate enzymatic degradation and improve mucosal permeability, thereby expanding the therapeutic potential of peptides beyond niche indications. This evolution is prompting pharmaceutical organizations to re-evaluate asset portfolios, prioritizing molecules that can deliver meaningful clinical differentiation when formulated for oral administration.

Another major shift is the move toward patient-centric care models that reward oral options with improved convenience and adherence, which in turn influence payer dialogues and formulary decisions. Strategic partnerships between innovators, contract development and manufacturing organizations, and specialized excipient providers are accelerating time-to-proof-of-concept and de-risking scale-up pathways. Simultaneously, regulatory expectations have evolved to place greater weight on robust pharmacokinetic characterization and real-world adherence data, creating new evidence requirements for market entry. Collectively, these trends are converging to make oral peptides a high-priority axis of innovation, while also raising the bar for cross-functional coordination across R&D, regulatory, commercial, and supply chain teams.

Assessing how tariff adjustments up to 2025 have reshaped sourcing strategies, manufacturing siting decisions, and commercial contracting across the oral peptide value chain

The cumulative impact of tariff changes instituted through 2025 has introduced measurable shifts in how organizations source key inputs, structure manufacturing footprints, and negotiate commercial terms. Elevated import duties on select chemical precursors, excipients, and equipment have amplified the importance of supply chain resilience and cost transparency. As a result, companies are increasingly factoring tariff exposure into supplier selection, negotiating longer-term contracts to stabilize landed cost, and prioritizing suppliers with diversified logistics corridors and near-shore capabilities.

These trade-related pressures are also incentivizing strategic investments in domestic manufacturing capacity and in-country finishing operations to reduce exposure to cross-border tariff volatility. For some developers, higher import costs have prompted a re-examination of formulation strategies to identify alternative excipients or to adopt manufacturing technologies that consolidate steps and reduce reliance on imported intermediates. In parallel, procurement and commercial teams are revisiting pricing models and contracting structures to preserve affordability for healthcare systems while maintaining viable margins. The cumulative result is a supply chain that is becoming more regionally oriented, more collaborative, and more focused on operational flexibility to absorb policy-driven disruptions.

Deep segmentation-driven insights that align therapeutic targets, formulation formats, distribution pathways, care settings, and molecule classes to optimize development and commercialization choices

Segmentation analysis reveals differentiated opportunities and technical requirements across therapeutic targets, dosage forms, channels of distribution, end-user settings, and molecular classes. When viewed by therapeutic application, notable distinctions emerge: programs targeting cardiovascular disorders require formulations and regimens that integrate with chronic care pathways; diabetes-focused development spans DPP-4 inhibitors, GLP-1 analogues, and insulin peptides each of which presents unique absorption and dosing challenges; gastrointestinal disorders prioritize local gut stability and tolerability; and oncology assets such as kinase inhibitors and peptide vaccines impose stringent efficacy and safety evidence expectations. These therapeutic nuances directly influence formulation choices and clinical development planning.

Form-related segmentation highlights that capsules, oral solutions, oral suspensions, and tablets each present trade-offs between stability, manufacturability, and patient acceptability, with selection driven by molecule properties and intended use. Distribution channel dynamics differ materially across hospital pharmacies, online pharmacies, and retail pharmacies, affecting procurement cycles, cold chain practices, and patient access models. End-user segmentation into clinics, home care settings, hospitals, and specialty centers underscores divergent requirements for dosing support, adherence monitoring, and provider education. Finally, molecule type-whether modified peptides, native peptides, or peptide mimetics-dictates chemical stability, susceptibility to enzymatic degradation, and formulation strategy. Integrating these segmentation lenses enables more precise targeting of development investments, regulatory strategies, and commercialization plans tailored to therapeutic class and care setting realities.

How regional regulatory landscapes, manufacturing strengths, and disease burdens across the Americas, Europe Middle East & Africa, and Asia-Pacific are directing oral peptide commercialization strategies

Regional dynamics continue to shape the trajectory of oral peptide adoption with distinct opportunities and constraints across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, innovation centers and concentrated payer systems favor early adoption of orally bioavailable peptides that demonstrate clear improvements in adherence and outcomes, while regulatory pathways and commercial infrastructure support rapid scale-up for clinically differentiated candidates. Across Europe, Middle East & Africa, heterogeneous regulatory environments and variable reimbursement approaches necessitate tailored market access strategies that reflect national HTA processes and pricing sensitivities.

The Asia-Pacific region combines strong manufacturing capacity with growing clinical demand, creating fertile ground for both originator companies and regional developers. High disease prevalence for indications such as diabetes and cardiovascular disorders heightens the strategic importance of cost-effective oral options and fosters partnerships between global firms and local manufacturers. Across all regions, geopolitical dynamics, logistics networks, and local regulatory expectations shape decisions on where to locate manufacturing and how to sequence launches, making region-specific planning an essential component of any global oral peptide strategy.

Mapping where strategic partnerships, manufacturing scale-up investments, and platform licensing are concentrating competitive advantage in the evolving oral peptide sector

Key company activity is characterized by strategic alliances, platform licensing, and targeted investments in specialized manufacturing and formulation capabilities. Leading pharmaceutical and biotechnology firms are placing priority bets on oral delivery platforms that can be applied across multiple peptide classes, while specialized technology firms focus on excipients, permeation enhancers, and encapsulation approaches that unlock systemic exposure. Contract development and manufacturing organizations are expanding aseptic and non-aseptic capabilities to accommodate peptide API and finished-dose production, and service providers are differentiating through integrated development pathways that reduce scale-up risk.

Competitive dynamics also reflect a bifurcation between large incumbents with portfolio breadth and agility, and nimble biotech firms that advance novel molecules or delivery modalities through early clinical validation. Licensing transactions and strategic collaborations play a central role in accelerating development timelines, enabling innovators to combine molecular expertise with specialized formulation know-how. Across the ecosystem, companies that can demonstrate reproducible manufacturing, robust clinical evidence, and a clear route to patient access are best positioned to convert scientific promise into commercial success.

Actionable strategic recommendations for executives to secure competitive advantage through platform investments, supply chain resilience, and evidence-driven access strategies

Industry leaders should adopt an integrated, multi-dimensional strategy to convert scientific advances into durable market positions. Prioritize investments in oral delivery platforms that offer broad applicability across peptide classes, while simultaneously advancing molecule-specific formulation development to de-risk pivotal studies. Strengthening supplier relationships and diversifying sourcing footprints will mitigate tariff and logistics risk, and targeted investments in regional manufacturing or finishing capabilities can provide cost and lead-time advantages.

Commercial strategies should align with payer and provider expectations by generating evidence that links oral administration to real-world adherence and outcomes. Engage early with regulators and health technology assessors to clarify evidence requirements and to design studies that address both efficacy and pragmatic usage. Form cross-functional teams that include formulation scientists, clinical development leads, regulatory experts, and commercial strategists to ensure decision-making reflects end-to-end implications. Finally, pursue flexible partnership models that enable rapid access to specialized capabilities while preserving optionality for future scale-up and geographic expansion.

A rigorous multi-method research approach combining expert interviews, literature synthesis, regulatory document review, and scenario validation to underpin strategic conclusions

The research underpinning these insights integrates multi-source qualitative and quantitative techniques designed to triangulate findings and minimize bias. Primary inputs include structured interviews with R&D leaders, regulatory specialists, manufacturing heads, payers, and clinical investigators, complemented by synthesis of peer-reviewed literature, regulatory guidance documents, and company disclosures. Comparative analysis across therapeutic areas and molecule types employed a consistent framework to evaluate technical risk, clinical development complexity, and commercial considerations.

Validation steps included cross-referencing interview inputs with observable regulatory filings and manufacturing announcements, conducting scenario testing for supply chain and tariff impacts, and soliciting external expert review to challenge assumptions. Limitations of the methodology are acknowledged: the rapidly evolving technology landscape means some platform capabilities may progress faster than documented public disclosures, and proprietary commercial terms remain confidential. Nonetheless, the methodological rigor applied here supports robust, actionable insights for decision-makers navigating oral peptide development and commercialization.

Concluding synthesis that connects formulation breakthroughs, regulatory engagement, and commercial execution into a practical roadmap for realizing the potential of oral peptide medicines

In conclusion, oral peptide therapeutics are transitioning from conceptual promise to tangible clinical and commercial reality, driven by rapid advances in delivery science, strategic partnerships, and evolving healthcare priorities that favor patient-centric regimens. Success in this space will depend on integrated approaches that align molecule selection, formulation innovation, regulatory strategy, and supply chain design with the distinct demands of therapeutic area and regional markets. Stakeholders that proactively address technical risks, engage payers and regulators early, and structure flexible manufacturing footprints will be best positioned to translate scientific progress into durable market access and patient impact.

The pathway forward demands both technological expertise and commercial acuity: companies must combine rigorous clinical evidence generation with pragmatic commercialization plans that reflect regional dynamics and payer expectations. For leaders seeking to act on the opportunities described herein, the full report provides deeper scenario analysis, competitive benchmarking, and tactical guidance to operationalize these conclusions and accelerate value creation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Peptide Drugs Market, by Form

  • 8.1. Capsules
  • 8.2. Oral Solutions
  • 8.3. Oral Suspensions
  • 8.4. Tablets

9. Oral Peptide Drugs Market, by Molecule Type

  • 9.1. Modified Peptides
  • 9.2. Native Peptides
  • 9.3. Peptide Mimetics

10. Oral Peptide Drugs Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Oral Peptide Drugs Market, by Application

  • 11.1. Cardiovascular Disorders
  • 11.2. Diabetes
    • 11.2.1. DPP-4 Inhibitors
    • 11.2.2. GLP-1 Analogues
    • 11.2.3. Insulin Peptides
  • 11.3. Gastrointestinal Disorders
  • 11.4. Oncology
    • 11.4.1. Kinase Inhibitors
    • 11.4.2. Peptide Vaccines

12. Oral Peptide Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care Settings
  • 12.3. Hospitals
  • 12.4. Specialty Centers

13. Oral Peptide Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Oral Peptide Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oral Peptide Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Oral Peptide Drugs Market

17. China Oral Peptide Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Biocon
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. Eli Lilly and Company
  • 18.11. F. Hoffmann-La Roche Ltd.
  • 18.12. i2o Therapeutics
  • 18.13. Intract Pharma
  • 18.14. Ipsen S.A.
  • 18.15. Merck & Co., Inc.
  • 18.16. Novartis AG
  • 18.17. Novo Nordisk A/S
  • 18.18. Oramed Pharmaceuticals Inc.
  • 18.19. Pfizer Inc.
  • 18.20. Protagonist Therapeutics, Inc.
  • 18.21. Sanofi S.A.
  • 18.22. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL PEPTIDE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORAL PEPTIDE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY MODIFIED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY MODIFIED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY MODIFIED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY NATIVE PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY NATIVE PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY NATIVE PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE MIMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE MIMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE MIMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GLP-1 ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GLP-1 ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GLP-1 ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY INSULIN PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY INSULIN PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY INSULIN PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 154. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 158. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 178. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 182. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 186. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 190. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)